HBOT for Wound Healing in Ireland: When It Helps

Hyperbaric oxygen therapy is marketed in Ireland for a long list of things, from sports recovery to brain fog, and for most of that list the evidence is thin. Chronic wounds are the exception. This is the area where randomised trials have actually been run, where international hyperbaric units accept referrals, and where the treatment has a plausible and measurable mechanism rather than a vague one.

That makes wound care the most useful place to look if you want to understand what hyperbaric oxygen can honestly do. The evidence here is not uniformly positive, which is precisely what makes it informative: a Cochrane review and a more recent guideline meta-analysis reach noticeably different conclusions about amputation, and reading why they differ tells you more about this treatment than any clinic page will.

This article covers what the trials found for diabetic foot ulcers and other chronic wounds, where the evidence runs out entirely, how wound-related hyperbaric oxygen is actually accessed in Ireland, what the risks are, and what it costs privately. It is general information rather than medical advice, and a non-healing wound is a reason to see a doctor rather than to book a chamber.

A wound needs oxygen to heal. Fibroblasts need it to lay down collagen, white cells need it to kill bacteria, and new blood vessels need it to grow into the wound bed. In a chronic wound, particularly on the foot of someone with diabetes and narrowed arteries, the tissue is often too poorly perfused to supply what repair requires, and the wound stalls in a state that can persist for months.

Hyperbaric oxygen attacks that specific problem. Breathing close to pure oxygen at greater than atmospheric pressure dissolves far more oxygen directly into the plasma than breathing air ever can, which raises tissue oxygen levels well beyond what supplemental oxygen at normal pressure achieves. The proposed knock-on effects include better bacterial killing, stimulation of new blood vessel growth, and reduced tissue swelling.

That reasoning is sound, and it is why hyperbaric units use transcutaneous oxygen measurement to check whether a particular patient's tissue actually responds to pressure before committing them to a course. It is also, on its own, only a mechanism. Mechanistic plausibility is not an outcome, and the question of whether it closes more wounds in real patients has to be answered by trials rather than by physiology.

The most careful synthesis remains the 2015 Cochrane review by Kranke and colleagues, which pooled 12 randomised trials with 577 participants in total, 10 of those trials and 531 of those participants being people with a diabetic foot ulcer. Pooling five trials with 205 participants, it found an increase in the rate of ulcer healing with hyperbaric oxygen at six weeks, with a risk ratio of 2.35 and a confidence interval running from 1.19 to 4.62. At longer-term follow-up out to one year, that benefit was no longer evident.

The review's authors were deliberately restrained about their own result. They concluded that hyperbaric oxygen improved the ulcers healed in the short term but not the long term, and stated plainly that the trials had various flaws in design or reporting which meant they were not confident in the findings. That is an unusual thing for a review to say about its own headline number, and it deserves to be repeated whenever the six-week figure is quoted.

More recent work is somewhat more favourable on healing. A 2025 meta-analysis published in Acta Diabetologica, carried out to support the Italian guidelines for treating diabetic foot syndrome, pooled 51 randomised trials across five different adjuvant treatments, eight of them testing hyperbaric oxygen. It found that every adjuvant therapy examined, hyperbaric oxygen included, produced a significantly higher ulcer healing rate and a shorter time to healing than standard care alone, and rated the quality of evidence for that healing endpoint as high.

For anyone with a diabetic foot ulcer, the outcome that matters is not how a wound looks at six weeks but whether the leg is still there in a year. This is where the two syntheses part company, and the disagreement is worth understanding rather than glossing over.

Cochrane, pooling five trials with 312 participants, found a risk ratio for major amputation of 0.36 with a confidence interval from 0.11 to 1.18. The central estimate suggests fewer amputations, but because the interval crosses 1.0 the result was not statistically significant, meaning chance cannot be excluded as the explanation. The 2025 Acta Diabetologica meta-analysis, working from a larger and more recent set of trials, did reach significance: hyperbaric oxygen was associated with a lower risk of major amputation, with an odds ratio of 0.28 and a confidence interval from 0.10 to 0.79. Platelet-rich plasma and fibrin were the only other adjuvant therapy in that analysis to show the same effect.

A 2026 systematic review in Medicina, which examined 22 studies comparing negative pressure wound therapy and hyperbaric oxygen, also reported that hyperbaric oxygen significantly reduced major amputations, while noting that no adequate head-to-head randomised trials exist to say which of the two therapies is better. The honest summary is that the amputation signal has strengthened as more trials have accumulated, and that it is a signal from pooled trials of varying quality rather than a settled fact. Anyone being offered hyperbaric oxygen for a threatened limb should be told both of those things.

Outside the diabetic foot, the trial evidence thins out very quickly. The Cochrane review identified a single randomised trial in venous leg ulcers, with 16 participants, which suggested a benefit in ulcer area reduction at six weeks. It found one further trial of 30 participants with a mix of non-healing diabetic and venous ulcers, reporting a reduction in ulcer area at the end of 30 days of treatment. Numbers that small can be a starting point for research but they cannot support a recommendation.

For arterial ulcers and pressure ulcers, the review identified no randomised trials at all. That is an absence of evidence rather than evidence of absence, but it means anyone offering hyperbaric oxygen for a pressure sore is working well beyond what has been tested in a controlled setting.

Two further wound-adjacent indications are widely accepted by hyperbaric medicine services internationally and are worth knowing about, because they are among the reasons hospital units exist: complications of radiotherapy affecting previously irradiated tissue, and severe soft tissue infections such as necrotising fasciitis, where hyperbaric oxygen is used alongside surgery and antibiotics rather than instead of them. Those are emergency and specialist pathways, not treatments anyone books for themselves.

This is where Irish practice differs sharply from the wellness market. Medical hyperbaric oxygen in the Republic runs through the National Hyperbaric Medicine Unit at University Hospital Galway, and referrals for accepted indications come from consultants rather than from patients or, in general, from GPs. A 2019 feature in the Irish Medical Times described the Irish landscape in some detail, including a medically run Dublin facility accredited by the Undersea and Hyperbaric Medical Society, and reported that patients referred for accepted indications, diabetic wounds among them, receive a full medical assessment by a hyperbaric-trained physician including transcutaneous oxygen measurement before a course begins.

Standard care comes first, and this is the most important practical point in the article. Diabetic foot ulcers in Ireland are managed through HSE multidisciplinary foot teams under the Diabetic Foot Model of Care, published in December 2021 by the National Clinical Programme for Diabetes, which sets out risk-stratified pathways and puts active foot disease in the hands of a specialist team working with vascular surgery, orthopaedics and orthotics. Offloading pressure from the ulcer, debriding dead tissue, controlling infection and assessing whether the blood supply can be restored surgically are the interventions that change outcomes. Hyperbaric oxygen, in every trial discussed above, was tested as an addition to that care rather than as a substitute for it.

On funding, the same Irish Medical Times report noted that at least one Irish health insurer had added hyperbaric oxygen to its covered procedures for accepted indications, and that some hospitals fund a block of sessions from their own budgets, with patients paying privately for further sessions beyond that. Insurance and public funding arrangements change, so the practical step is to ask the referring consultant what is covered in your case rather than to assume either way.

Gerovia lists nineteen providers offering hyperbaric oxygen therapy across Ireland and Northern Ireland, including clinics in Dublin, Galway, Cork, Limerick and Belfast, and the great majority of those are private wellness settings that you can book directly. They vary enormously, and the variation matters more for wounds than for anything else hyperbaric oxygen is sold for.

The randomised trials in diabetic foot ulcers used medical protocols in hard chambers: pressures around twice atmospheric pressure or higher, close to pure oxygen, sessions of roughly 90 minutes, repeated daily on weekdays for several weeks, with medical staff present and a physician responsible for the course. A soft-shell chamber running at a small fraction above atmospheric pressure delivers a different physiological dose entirely. Whatever such a chamber may or may not do, the wound-healing evidence above was not generated with one and does not transfer to it.

The practical implication is narrow but firm. If you have a chronic wound, the route is your GP or diabetic foot team and, if appropriate, a consultant referral to a hyperbaric unit that will assess your tissue oxygenation first. Booking a wellness chamber on your own initiative for a foot ulcer risks delaying the offloading, debridement and vascular assessment that carry the real weight, and delay is the thing that costs people toes and feet.

Hyperbaric oxygen is not a benign spa treatment, and the trial data reflect that. The 2025 Acta Diabetologica meta-analysis that found a reduction in major amputation also found a higher rate of serious adverse events with hyperbaric oxygen and with platelet-rich plasma than with standard care, which is exactly the sort of trade-off a clinician should be discussing with a patient rather than smoothing over.

The common problems are mechanical and pressure-related. Middle ear barotrauma is the most frequent, which is why units teach ear-clearing techniques and why a blocked nose or a heavy cold postpones a session. Sinus discomfort follows the same logic. Temporary short-sightedness can develop over a long course of treatment and typically settles over weeks after it ends. Oxygen toxicity causing a seizure is rare but is the reason sessions are supervised and time-limited, and confinement anxiety is common enough that units screen for it. An untreated pneumothorax is the classic absolute reason not to enter a chamber, and several medical conditions and medicines, including some chemotherapy agents, need specialist review before a course. That review is part of what a hyperbaric physician is for.

None of this makes hyperbaric oxygen dangerous in competent hands. It does mean that a course of daily pressurised sessions is a medical undertaking, that it belongs with staff trained to manage those specific complications, and that a facility you can simply walk into off the street is not, by definition, screening you for them.

In the Republic of Ireland, a single private hyperbaric session in 2026 typically costs between EUR 100 and EUR 150, with a commonly quoted single-session rate around EUR 135. Packages are where the price drops: a five-session block often works out near EUR 120 a session, ten sessions near EUR 110, and larger blocks of twenty sessions around EUR 100 each, putting a full course in the low thousands. Some clinics also ask you to buy a personal reusable mask for hygiene reasons as a one-off cost. Prices last checked September 2026 and vary by clinic, so confirm current rates directly.

Before paying for anything, ask four questions. What pressure does this chamber operate at, in atmospheres absolute, and is it a hard chamber? Who is the doctor responsible for my course, and are they trained in hyperbaric medicine? Will my tissue oxygenation be measured before we start, so that we know whether I am the sort of patient who responds? And has my wound been assessed by a specialist foot or vascular team, and does that team agree that hyperbaric oxygen is a reasonable addition now?

If the answer to the last question is no, that is the place to start rather than the chamber. The evidence reviewed in this article supports hyperbaric oxygen as an adjunct to good wound care in a specific population, with a short-term healing benefit that Cochrane itself treated cautiously and an amputation benefit that later pooled analyses support more strongly. Used that way, in the right patient, it is a reasonable treatment. Used as a substitute for specialist foot care, it is an expensive delay.